Dimitri H.J. Buytaert’s Post

LAST chance to register for our Webcast. Dr. Carl June and Christopher Ung will engage in an insightful fireside chat-style discussion on the challenges and future trends in the CAR T-cell therapy space, including: Academic and Industry Partnership in CAR-T Development; CAR-T Development in US and China; Biomarkers from Vein to Vein: Mechanism, Selection, and Resistance; Facing the Challenges: Adverse Events and Patient Resistance; New Frontiers: Solid Tumors, Evolutionary and Revolutionary CAR models. You get the opportunity to submit questions on registration. This is a fantastic chance to get answers on topical questions in the CAR-T space from a pioneer and leader in the field. Here’s the link to register: https://bit.ly/3Urva6p

Healixia - the Belgian community of all professionals active along the life cycle of medicines, medical devices, in vitro diagnostics & other health related products. Members are active in research & development (including pre-clinical, early clinical and later phases), medical affairs, safety, regulatory affairs and market access in industry, academia, investigator sites, authorities, regulatory bodies or in consultancy - Join us at the end of spring for an informal get-together, where you can meet long-known and new peers over some good food and drinks.

CellCarta acquisition of Biogazelle #cellcarta; #biogazelle CellCarta has completed the acquisition of Biogazelle, a specialty CRO with a focus on nucleic acid quantification service for preclinical and clinical development. The company has a team of 45 full-time employees and is located in Ghent, Belgium in a facility of 750 m2. The addition of Biogazelle to the CellCarta family allows us to expand our existing genomic capabilities with high-end digital PCR, and strengthen our quantitative PCR and RNAseq assays. While continuing to offer its current breadth of genomic services, Biogazelle will become CellCarta’s Center of Excellence for the development of complex genomic biomarker assays. The acquisition allows CellCarta to expand its offering to clients in fields with high demand in genomic analysis, such as immuno-oncology and cell and gene therapy. Biogazelle has high scientific expertise and is internationally recognized for setting standards in gene expression analysis. We’re very excited to welcome them to our team!

Don't miss out the Healixia Annual Conference - NOVEMBER 23rd. 'Current and future trends in patient centric solutions for healthcare'. You will appreciate the final program with following distinguished speakers: Noël Wathion (former Deputy Executive Director EMEA), Stefanie Veraghtert, Benoit Brouwers - #healthcare #clinicalresearch

Do you know Healixia? Founded in 2020, and with 600+ members: we are the largest community for professionals in the Belgian health eco-system. Our professionals are active in early development, clinical research, regulatory affairs and medical affairs. More info on www.healixia.be #clinicalresearch #regulatoryaffairs

PRESS RELEASE: We’re excited to announce the acquisition of Reveal Biosciences a leading company that combines computational histopathology with #AI pathology solutions. For more information: https://bit.ly/3vWilS1 #CellCarta #CROlaboratory #biomarkers #precisionmedicine #digitalpathology

Happy to announce the next big step in the growth of Caprion-HistoGeneX. We are rebranding as CellCarta, your partner of choice for Precision Medicine laboratory services. #CellCarta #precisionmedicine

Let's connect! #Healixia

HistoGeneX in the news - #innovation https://lnkd.in/dvfp9Mh